Gilead Sciences' (GILD) Yeytuo, or lenacapavir, has received approval from the UK Medicines and Healthcare products Regulatory Agency for the prevention of sexually transmitted HIV-1 infection in adults and adolescents, the agency said Friday.
The drug works by lowering the risk of the HIV-1 virus multiplying and spreading throughout the body if a person is exposed to the virus, the agency said.
Gilead Sciences did not immediately respond to MT Newswires' request for comment.
Shares of the company were up over 3% in recent Friday trading.
Price: 125.24, Change: +3.77, Percent Change: +3.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments